Replies to post #314165 on Avid Bioservices Inc (CDMO)

[patientlywaiting]

"By standardizing and validating biomarkers for immunotherapy while also developing and exploring new biomarkers, we hope to advance rapidly toward a new future of precision oncology that benefits all patients," Collins told the briefing."